Ensartinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 124 publications

Ensartinib Combined with Radiotherapy for the Treatment of Advanced Primary  Pulmonary Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring  TPM3-ALK Fusion: A Case Report

Ensartinib Combined with Radiotherapy for the Treatment of Advanced Primary  Pulmonary Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring  TPM3-ALK Fusion: A Case Report

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: March 04, 2026

Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.

Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.

Journal: Lung cancer management

Published: February 03, 2026

Development and validation of a quick and sensitive UPLC-MS/MS method for measuring ensartinib in HLMs: investigation of structural alerts associated with metabolic lability and in silico toxicity.

Development and validation of a quick and sensitive UPLC-MS/MS method for measuring ensartinib in HLMs: investigation of structural alerts associated with metabolic lability and in silico toxicity.

Journal: The Analyst

Published: November 06, 2025

Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase-driven non-small cell lung cancer therapy.

Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase-driven non-small cell lung cancer therapy.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: October 01, 2025

Treatment with ensartinib improves postoperative survival in a patient with stage IIB LUAD carrying a rare ALK mutation: case report.

Treatment with ensartinib improves postoperative survival in a patient with stage IIB LUAD carrying a rare ALK mutation: case report.

Journal: Open life sciences

Published: September 09, 2025

Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib.

Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib.

Journal: NPJ precision oncology

Published: August 29, 2025

Comparison of the efficacy based on clinicopathological characteristics and the safety of first-line treatments for patients with advanced ALK rearrangement non-small cell lung cancer: a network meta-analysis.

Comparison of the efficacy based on clinicopathological characteristics and the safety of first-line treatments for patients with advanced ALK rearrangement non-small cell lung cancer: a network meta-analysis.

Journal: Frontiers in oncology

Published: August 01, 2025

Severe skin toxicity and early progression following neoadjuvant ensartinib and surgery in anaplastic lymphoma kinase-positive locally advanced lung cancer: a case report.

Severe skin toxicity and early progression following neoadjuvant ensartinib and surgery in anaplastic lymphoma kinase-positive locally advanced lung cancer: a case report.

Journal: Frontiers in pharmacology

Published: July 25, 2025

Ensartinib targeted conversion surgery for ALK-positive unresectable locally advanced non-small cell lung cancer: a case report.

Ensartinib targeted conversion surgery for ALK-positive unresectable locally advanced non-small cell lung cancer: a case report.

Journal: Journal of cardiothoracic surgery

Published: July 02, 2025

Amylase-producing lung adenocarcinoma with an anaplastic lymphoma kinase fusion mutation: a case report.

Amylase-producing lung adenocarcinoma with an anaplastic lymphoma kinase fusion mutation: a case report.

Journal: Laboratory medicine

Published: June 25, 2025

Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes.

Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes.

Journal: JTO clinical and research reports

Published: May 02, 2025

Clinical practice guideline on anaplastic lymphoma kinase-tyrosine kinase inhibitors for non-small cell lung cancer (2025 edition)

Clinical practice guideline on anaplastic lymphoma kinase-tyrosine kinase inhibitors for non-small cell lung cancer (2025 edition)

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: April 23, 2025

Showing 1-12 of 124

Last Updated: 04/28/2026